CY1112400T1 - Παραγωγα πυραζολοπυριμιδινης ως αναστολεις της εξαρτωμενης απο κυκλινη κινασης - Google Patents
Παραγωγα πυραζολοπυριμιδινης ως αναστολεις της εξαρτωμενης απο κυκλινη κινασηςInfo
- Publication number
- CY1112400T1 CY1112400T1 CY20111100349T CY111100349T CY1112400T1 CY 1112400 T1 CY1112400 T1 CY 1112400T1 CY 20111100349 T CY20111100349 T CY 20111100349T CY 111100349 T CY111100349 T CY 111100349T CY 1112400 T1 CY1112400 T1 CY 1112400T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- cycline
- pyrazolopyrimidine
- inclusions
- products
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108091007914 CDKs Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Στις πολλές πραγματοποιήσεις αυτής, η παρούσα εφεύρεση παρέχει μια νέα κατηγορία ενώσεων πυραζολο[1,5-α]πυριμιδίνης ως αναστολείς των εξαρτώμενων από κυκλίνη κινασών, μεθόδους παρασκευής τέτοιων ενώσεων, φαρμακευτικές συνθέσεις που περιέχουν μία ή περισσότερες τέτοιες ενώσεις, μεθόδους παρασκευής φαρμακοτεχνικών μορφών που περιλαμβάνουν μία ή περισσότερες τέτοιες ενώσεις και μεθόδους θεραπείας, αποτροπής, αναστολής ή ανακούφισης μιας ή περισσοτέρων ασθενειών που συνδυάζονται με τις CDKs χρησιμοποιώντας τέτοιες ενώσεις ή φαρμακευτικές συνθέσεις.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/776,988 US7119200B2 (en) | 2002-09-04 | 2004-02-11 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP05722809A EP1720882B1 (en) | 2004-02-11 | 2005-02-08 | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112400T1 true CY1112400T1 (el) | 2015-12-09 |
Family
ID=34860861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100349T CY1112400T1 (el) | 2004-02-11 | 2011-04-05 | Παραγωγα πυραζολοπυριμιδινης ως αναστολεις της εξαρτωμενης απο κυκλινη κινασης |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7119200B2 (el) |
| EP (1) | EP1720882B1 (el) |
| JP (2) | JP4845743B2 (el) |
| KR (1) | KR101196498B1 (el) |
| CN (1) | CN1946725B (el) |
| AR (1) | AR047543A1 (el) |
| AT (1) | ATE494287T1 (el) |
| AU (1) | AU2005212409C1 (el) |
| BR (1) | BRPI0507644B8 (el) |
| CA (1) | CA2555345C (el) |
| CY (1) | CY1112400T1 (el) |
| DE (1) | DE602005025733D1 (el) |
| DK (1) | DK1720882T3 (el) |
| ES (1) | ES2359410T3 (el) |
| HK (1) | HK1090926A1 (el) |
| HR (1) | HRP20110245T1 (el) |
| IL (1) | IL177283A (el) |
| MY (1) | MY149044A (el) |
| NO (1) | NO337520B1 (el) |
| NZ (1) | NZ590480A (el) |
| PE (1) | PE20050774A1 (el) |
| PL (1) | PL1720882T3 (el) |
| RU (1) | RU2414472C9 (el) |
| SI (1) | SI1720882T1 (el) |
| TW (1) | TWI393566B (el) |
| WO (1) | WO2005077954A2 (el) |
| ZA (1) | ZA200606573B (el) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004076458A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| GB0321475D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| WO2005035516A1 (ja) * | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
| JP2007536369A (ja) * | 2004-05-06 | 2007-12-13 | ファイザー・インク | プロリン及びモルホリン誘導体の新規化合物 |
| WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
| AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| DK1817282T3 (da) * | 2004-11-23 | 2011-10-10 | Astrazeneca Ab | Til behandling af respiratoriske sygdomme egnede phenoxy derivater |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP2008543761A (ja) * | 2005-06-09 | 2008-12-04 | シェーリング コーポレイション | ３−アミノ−４−置換ピラゾール誘導体の合成 |
| WO2007013964A1 (en) * | 2005-07-22 | 2007-02-01 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| WO2007017678A1 (en) * | 2005-08-09 | 2007-02-15 | Eirx Therapeutics Limited | Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them |
| NZ567151A (en) * | 2005-10-06 | 2012-03-30 | Schering Corp | Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases |
| CA2635760C (en) * | 2005-12-28 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| AU2007223865A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
| EP2027127A1 (en) * | 2006-05-22 | 2009-02-25 | Shering Corporation | Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors |
| EP2405270B1 (en) | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
| JP5247699B2 (ja) * | 2006-08-18 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | キラルピペリジンアルコールの分割プロセスおよびピペリジンアルコールを用いるピラゾロ−［１，５］−ピリミジン誘導体の合成プロセス |
| US7786306B2 (en) * | 2006-08-18 | 2010-08-31 | Schering Corporation | Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same |
| CN101627041A (zh) * | 2006-08-28 | 2010-01-13 | 先灵公司 | 合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体 |
| CA2661737C (en) * | 2006-08-28 | 2015-02-10 | Schering Corporation | Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates |
| BRPI0823416A2 (pt) | 2007-05-08 | 2015-06-16 | Schering Corp | Métodos de tratamento usando formulações intravenosas compreendendo temozolomida. |
| JP2010529140A (ja) * | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
| WO2009020140A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
| WO2009023160A2 (en) * | 2007-08-11 | 2009-02-19 | The Uab Research Foundation | Novel inhibitors of bacterial sortase enzymes and methods of using the same |
| JP6151879B2 (ja) | 2007-08-31 | 2017-06-21 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | 体細胞を再プログラミングすることにおけるｗｎｔ経路の刺激 |
| NZ584037A (en) * | 2007-09-17 | 2012-08-31 | Schering Corp | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| US20100286038A1 (en) * | 2007-09-21 | 2010-11-11 | Valentyn Antochshuk | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| EP2212432A4 (en) * | 2007-10-22 | 2011-10-19 | Schering Corp | COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES |
| JP2011519849A (ja) * | 2008-04-30 | 2011-07-14 | アクテリオン ファーマシューティカルズ リミテッド | ピペリジン及びピロリジン化合物 |
| CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| US20100035875A1 (en) * | 2008-06-20 | 2010-02-11 | Bing-Yan Zhu | Triazolopyridine jak inhibitor compounds and methods |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| WO2010068838A2 (en) * | 2008-12-11 | 2010-06-17 | Emory University | PROCESSES FOR PREPARING 5,7 DIAMINOPYRAZOLO[1,5-α] PYRIMIDINE COMPOUNDS |
| US8507673B2 (en) * | 2008-12-11 | 2013-08-13 | Emory University | Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds |
| WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| WO2010124290A2 (en) * | 2009-04-24 | 2010-10-28 | Whitehead Institute For Biomedical Research | Compositions and methods for deriving or culturing pluripotent cells |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US8993535B2 (en) | 2009-09-04 | 2015-03-31 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| EP2552917B1 (en) * | 2010-03-26 | 2014-11-05 | Merck Sharp & Dohme Corp. | Process for synthesizing 6-bromo-3-(1-methyl-1h-pyrazol-4-yl)-5-(3(r)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine |
| SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| EP2621926B1 (en) * | 2010-09-30 | 2017-08-30 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP4095236A1 (en) | 2011-09-30 | 2022-11-30 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| EP2634189A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2634190A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP2831282B1 (en) | 2012-03-30 | 2018-07-04 | Merck Sharp & Dohme Corp. | Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CA2889919C (en) | 2012-11-16 | 2021-08-17 | University Health Network | Pyrazolopyrimidine compounds |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US9556169B2 (en) | 2012-11-19 | 2017-01-31 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| AU2014309199B2 (en) | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| RU2720408C2 (ru) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения ингибиторов atr киназы (варианты) |
| US11013743B2 (en) * | 2013-12-20 | 2021-05-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of CDK and ERK inhibitors |
| AU2015204566A1 (en) * | 2014-01-09 | 2016-08-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015130585A1 (en) | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| EP3148532B1 (en) | 2014-05-28 | 2021-03-03 | Piramal Enterprises Limited | Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer |
| RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
| WO2016077526A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| EP3273966B1 (en) * | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN106146515B (zh) * | 2015-04-17 | 2020-09-04 | 常州隆赛医药科技有限公司 | 新型激酶抑制剂的制备及应用 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法 |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017075629A2 (en) * | 2015-11-01 | 2017-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| CN116217729A (zh) | 2015-11-12 | 2023-06-06 | 思进公司 | 聚糖相互作用化合物及使用方法 |
| KR20180083902A (ko) | 2015-11-18 | 2018-07-23 | 젠자임 코포레이션 | 다낭성 신장병의 바이오마커 및 그의 용도 |
| MX2018009750A (es) | 2016-02-12 | 2019-02-07 | Bluebird Bio Inc | Composiciones potenciadoras de vcn y métodos para su uso. |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| EP4104837A3 (en) | 2016-04-15 | 2023-04-26 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| JP6943876B2 (ja) | 2016-04-15 | 2021-10-06 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
| UA127826C2 (uk) | 2016-05-18 | 2024-01-17 | Локсо Онколоджі, Інк. | СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN108017641B (zh) * | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| HUE057337T2 (hu) * | 2017-02-10 | 2022-05-28 | Novartis Ag | 1-(4-amino-5-bróm-6-(1H-pirazol-1-il)pirimidin-2-il)-1H-pirazol-4-ol és alkalmazása rák kezelésében |
| JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| MX2020001103A (es) | 2017-07-28 | 2020-08-17 | Nimbus Lakshmi Inc | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. |
| CA3095880A1 (en) | 2018-04-11 | 2019-10-17 | Qurient Co., Ltd. | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| AU2019360941A1 (en) * | 2018-10-15 | 2021-04-29 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| US11155560B2 (en) | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
| TW202038957A (zh) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與激酶抑制劑之組合 |
| US11780842B2 (en) | 2019-03-26 | 2023-10-10 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| MX2022005563A (es) | 2019-11-08 | 2022-08-19 | Ventyx Biosciences Inc | Ligandos de la pseudoquinasa tyk2. |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| WO2021224633A1 (en) | 2020-05-06 | 2021-11-11 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| CN116262752A (zh) * | 2021-12-15 | 2023-06-16 | 上海壹迪生物技术有限公司 | 吡唑并嘧啶类化合物及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US619131A (en) * | 1899-02-07 | Chester l | ||
| BE792533A (fr) * | 1971-12-09 | 1973-06-08 | Int Chem & Nuclear Corp | Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation |
| JPS6157587A (ja) * | 1984-08-29 | 1986-03-24 | Shionogi & Co Ltd | 縮合複素環誘導体および抗潰瘍剤 |
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| DK0591528T3 (da) | 1991-04-22 | 1999-08-23 | Otsuka Pharma Co Ltd | Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette |
| RU2142946C1 (ru) * | 1992-12-17 | 1999-12-20 | Пфайзер Инк. | Производные пиразола и фармацевтическая композиция, содержащая их |
| US5571813A (en) | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| EP0628559B1 (en) | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Pyrimidine compounds and their use as pharmaceuticals |
| JP3710502B2 (ja) * | 1993-10-21 | 2005-10-26 | 塩野義製薬株式会社 | 三環性化合物 |
| CA2169719C (en) | 1994-06-21 | 2002-04-16 | Yasuo Shoji | Pyrazolo[1,5-a]pyrimidine derivative |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| FR2750048B1 (fr) * | 1996-06-21 | 1998-08-14 | Oreal | Compositions de teinture des fibres keratiniques contenant des derives pyrazolo-(1, 5-a)-pyrimidine, procede de teinture, nouveaux derives pyrazolo-(1, 5-a)-pyrimidine et leur procede de preparation |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| ATE340176T1 (de) * | 1996-08-28 | 2006-10-15 | Pfizer | Substituierte 6,5-heterobicyclische-derivate |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| CA2314355A1 (en) | 1997-12-13 | 1999-06-24 | Bristol-Myers Squibb Company | Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors |
| US6413974B1 (en) | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| FR2805160B1 (fr) * | 2000-02-23 | 2002-04-05 | Oreal | Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture |
| DE60122176T2 (de) | 2000-09-15 | 2007-07-05 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazole und ihre verwendung als erk-inhibitoren |
| US7067520B2 (en) | 2000-11-17 | 2006-06-27 | Ishihara Sangyo Kaisha, Ltd. | Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts |
| CA2432417A1 (fr) | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| WO2003091256A1 (fr) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive |
| DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| JP2006501260A (ja) * | 2002-09-04 | 2006-01-12 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002571A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| WO2004076458A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| WO2005035516A1 (ja) * | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
-
2004
- 2004-02-11 US US10/776,988 patent/US7119200B2/en not_active Expired - Lifetime
-
2005
- 2005-02-05 TW TW094104016A patent/TWI393566B/zh active
- 2005-02-08 AU AU2005212409A patent/AU2005212409C1/en active Active
- 2005-02-08 EP EP05722809A patent/EP1720882B1/en active Active
- 2005-02-08 CA CA2555345A patent/CA2555345C/en active Active
- 2005-02-08 DE DE602005025733T patent/DE602005025733D1/de active Active
- 2005-02-08 WO PCT/US2005/003859 patent/WO2005077954A2/en active Application Filing
- 2005-02-08 ES ES05722809T patent/ES2359410T3/es active Active
- 2005-02-08 CN CN2005800122934A patent/CN1946725B/zh active Active
- 2005-02-08 PL PL05722809T patent/PL1720882T3/pl unknown
- 2005-02-08 JP JP2006553181A patent/JP4845743B2/ja active Active
- 2005-02-08 DK DK05722809.0T patent/DK1720882T3/da active
- 2005-02-08 NZ NZ590480A patent/NZ590480A/en unknown
- 2005-02-08 SI SI200531260T patent/SI1720882T1/sl unknown
- 2005-02-08 KR KR1020067016132A patent/KR101196498B1/ko active IP Right Grant
- 2005-02-08 AT AT05722809T patent/ATE494287T1/de active
- 2005-02-08 MY MYPI20050514A patent/MY149044A/en unknown
- 2005-02-08 RU RU2006132288/04A patent/RU2414472C9/ru active
- 2005-02-08 BR BRPI0507644A patent/BRPI0507644B8/pt active IP Right Grant
- 2005-02-10 AR ARP050100483A patent/AR047543A1/es active IP Right Grant
- 2005-02-10 PE PE2005000156A patent/PE20050774A1/es active IP Right Grant
-
2006
- 2006-03-31 US US11/396,079 patent/US20070054925A1/en not_active Abandoned
- 2006-08-03 IL IL177283A patent/IL177283A/en active IP Right Grant
- 2006-08-07 ZA ZA200606573A patent/ZA200606573B/xx unknown
- 2006-09-08 NO NO20064046A patent/NO337520B1/no unknown
- 2006-11-22 HK HK06112804.5A patent/HK1090926A1/xx unknown
-
2010
- 2010-07-09 JP JP2010157338A patent/JP2010215675A/ja not_active Withdrawn
-
2011
- 2011-04-04 HR HR20110245T patent/HRP20110245T1/hr unknown
- 2011-04-05 CY CY20111100349T patent/CY1112400T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112400T1 (el) | Παραγωγα πυραζολοπυριμιδινης ως αναστολεις της εξαρτωμενης απο κυκλινη κινασης | |
| ATE470668T1 (de) | Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs | |
| DK1537116T3 (da) | Pyrazolopyrimidiner egnede til behandling af cancersygdomme | |
| MY139336A (en) | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| BRPI0616987A2 (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
| TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| MX2009011355A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. | |
| TW200745123A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| MY137888A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MY137843A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MX2009005011A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
| MY134589A (en) | Imidazopyrazines as cyclin dependent kinase inhibitors | |
| CY1110666T1 (el) | Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων | |
| MX2009003733A (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| WO2007044401A3 (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
| MY133311A (en) | Novel imidazopyridines as cyclin dependent kinase inhibitors | |
| MX2009003734A (es) | Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina. | |
| MXPA05007352A (es) | Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion. | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| MY136840A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
| ATE546452T1 (de) | Pyrazolopyrrolderivate als proteinkinaseinhibitoren |